Dual targeting of PAM and AR pathways yields encouraging results in mCRPCByAlice Bernard-Tessier, MDNovember 13th 2025Alice Bernard-Tessier, MD, highlights preliminary results from a phase 1 trial of gedatolisib plus darolutamide in mCRPC.